Crossed cerebellar diaschisis in Alzheimer's disease.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
pubmed:
27
1
2022
medline:
18
3
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
Crossed cerebellar diaschisis (CCD) is characterized by hypometabolism and hypoperfusion on molecular imaging in the cerebellum due to a supratentorial lesion on the contralateral side. CCD is a well-established phenomenon in acute or subacute conditions such as infarction but it has been less well described in chronic conditions such as neurodegenerative dementias. Here, we investigate CCD in a large sample of 830 people meeting research criteria for Alzheimer's disease (AD) using [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET). This study is based on FDG-PET data collected at baseline as part of two large-scale Phase III clinical trials of a novel tau aggregation inhibitor medication, methylthioninium in mild to moderate AD participants. Quantification of FDG-PET hypometabolism was carried out using standardized uptake value ratio (SUVR), with the pons as the comparison region. SUVR was compared in different regions of interest between the right and left hemispheres of the brain and cerebellum in people with mild AD (Mini-Mental State Examination score ≥ 20). Comparison of SUVR in different brain regions demonstrated significant differences in the temporal, occipital and cerebellar cortices. Right and left asymmetry was noted with lower SUVR in the left temporal and occipital regions, whereas SUVR was lower in the right side of the cerebellum. Here, we found robust evidence of CCD in a large sample of people with AD, a chronic neurodegenerative condition. The presence of this phenomenon in AD opens up a new avenue of research in AD pathogenesis and has the potential to change future diagnostic and therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Crossed cerebellar diaschisis (CCD) is characterized by hypometabolism and hypoperfusion on molecular imaging in the cerebellum due to a supratentorial lesion on the contralateral side. CCD is a well-established phenomenon in acute or subacute conditions such as infarction but it has been less well described in chronic conditions such as neurodegenerative dementias. Here, we investigate CCD in a large sample of 830 people meeting research criteria for Alzheimer's disease (AD) using [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET).
MATERIALS AND METHODS
METHODS
This study is based on FDG-PET data collected at baseline as part of two large-scale Phase III clinical trials of a novel tau aggregation inhibitor medication, methylthioninium in mild to moderate AD participants. Quantification of FDG-PET hypometabolism was carried out using standardized uptake value ratio (SUVR), with the pons as the comparison region. SUVR was compared in different regions of interest between the right and left hemispheres of the brain and cerebellum in people with mild AD (Mini-Mental State Examination score ≥ 20).
RESULTS
RESULTS
Comparison of SUVR in different brain regions demonstrated significant differences in the temporal, occipital and cerebellar cortices. Right and left asymmetry was noted with lower SUVR in the left temporal and occipital regions, whereas SUVR was lower in the right side of the cerebellum.
CONCLUSION
CONCLUSIONS
Here, we found robust evidence of CCD in a large sample of people with AD, a chronic neurodegenerative condition. The presence of this phenomenon in AD opens up a new avenue of research in AD pathogenesis and has the potential to change future diagnostic and therapeutic strategies.
Identifiants
pubmed: 35081090
doi: 10.1097/MNM.0000000000001531
pii: 00006231-202204000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-427Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Förster A, Kerl HU, Goerlitz J, Wenz H, Groden C. Crossed cerebellar diaschisis in acute isolated thalamic infarction detected by dynamic susceptibility contrast perfusion MRI. PLoS One 2014; 9:e88044.
Baron JC, Bousser MG, Comar D, Castaigne P. “Crossed cerebellar diaschisis” in human supratentorial brain infarction. Trans Am Neurol Assoc 1981; 105:459–461.
Gold L, Lauritzen M. Neuronal deactivation explains decreased cerebellar blood flow in response to focal cerebral ischemia or suppressed neocortical function. Proc Natl Acad Sci USA 2002; 99:7699–7704.
Tanaka M, Kondo S, Hirai S, Ishiguro K, Ishihara T, Morimatsu M. Crossed cerebellar diaschisis accompanied by hemiataxia: a PET study. J Neurol Neurosurg Psychiatry 1992; 55:121–125.
Engelborghs S, Pickut BA, Mariën P, Opsomer F, De Deyn PP. Crossed cerebellar diaschisis and hemiataxia after thalamic hemorrhage. J Neurol 2000; 247:476–477.
Liu Y, Karonen JO, Nuutinen J, Vanninen E, Kuikka JT, Vanninen RL. Crossed cerebellar diaschisis in acute ischemic stroke: a study with serial SPECT and MRI. J Cereb Blood Flow Metab 2007; 27:1724–1732.
O’Gorman RL, Siddiqui A, Alsop DC, Jarosz JM. Perfusion MRI demonstrates crossed-cerebellar diaschisis in sickle cell disease. Pediatr Neurol 2010; 42:437–440.
Agarwal KK, Tripathi M, Karunanithi S, Das CJ, Suri V, Nalwa A. Crossed cerebellar diaschisis in cerebral toxoplasmosis demonstrated on 18 F-FDG PET/CT. Rev Esp Med Nucl Imagen Mol 2014; 33:397–398.
Otte A, Roelcke U, von Ammon K, Hausmann O, Maguire RP, Missimer J, et al. Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine. J Neurol Sci 1998; 156:73–77.
Takane Y, Shibata K, Nishimura Y, Sakura H. Crossed cerebellar and contralateral thalamic hyperperfusion in epilepsy. Intern Med 2017; 56:1121–1122.
Reesink FE, García DV, Sánchez-Catasús CA, Peretti DE, Willemsen AT, Boellaard R, et al. Crossed cerebellar diaschisis in Alzheimer’s disease. Curr Alzheimer Res 2018; 15:1267–1275.
Hertel A, Wenz H, Al-Zghloul M, Hausner L, FrÖlich L, Groden C, FÖrster A. Crossed cerebellar diaschisis in Alzheimer’s disease detected by arterial spin-labelling perfusion MRI. In Vivo 2021; 35:1177–1183.
Franceschi AM, Clifton MA, Naser-Tavakolian K, Ahmed O, Bangiyev L, Clouston S, Franceschi D. FDG PET/MRI for visual detection of crossed cerebellar diaschisis in patients with dementia. AJR Am J Roentgenol 2021; 216:165–171.
Schelter BO, Shiells H, Baddeley TC, Rubino CM, Ganesan H, Hammel J, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer’s disease. J Alzheimers Dis 2019; 72:931–946.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:263–269.
Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 2003; 23:994–1005.
Derflinger S, Sorg C, Gaser C, Myers N, Arsic M, Kurz A, et al. Grey-matter atrophy in Alzheimer’s disease is asymmetric but not lateralized. J Alzheimers Dis 2011; 25:347–357.
Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett DA, et al. At the interface of sensory and motor dysfunctions and Alzheimer’s disease. Alzheimers Dement 2015; 11:70–98.
Amemiya K, Morita T, Saito DN, Ban M, Shimada K, Okamoto Y, et al. Local-to-distant development of the cerebrocerebellar sensorimotor network in the typically developing human brain: a functional and diffusion MRI study. Brain Struct Funct 2019; 224:1359–1375.
Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFinder Study. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat Commun 2020; 11:2612.